UK markets open in 2 hours 18 minutes

CytRx Corporation (CYTR)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.7200-0.0150 (-2.04%)
At close: 12:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.7350
Open0.7450
Bid0.0000 x 1100
Ask0.0000 x 1000
Day's range0.7000 - 0.7500
52-week range0.2300 - 0.8500
Volume39,042
Avg. volume44,498
Market cap26.266M
Beta (5Y monthly)1.72
PE ratio (TTM)N/A
EPS (TTM)-0.2440
Earnings date16 Nov 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • CytRx Comments on Quarterly Results and Recent Strategic Progress
    Business Wire

    CytRx Comments on Quarterly Results and Recent Strategic Progress

    CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today commented on its results for the third quarter ended September 30, 2020. In addition, CytRx highlighted recent steps to support Centurion Biopharma’s progress as well as external developments pertaining to its agreements with ImmunityBio, Inc. ("ImmunityBio") and Orphazyme A/S ("Orphazyme"). The Company’s 10-Q was filed on November 13, 2020.

  • CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C
    Business Wire

    CytRx Highlights Orphazyme’s Submission of European Marketing Authorisation for Arimoclomol to Treat Niemann-Pick Disease Type C

    CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA) (NASDAQ:ORPH) ("Orphazyme") has submitted a Marketing Authorisation Application ("MAA") to the European Medicines Agency ("EMA") for arimoclomol in the treatment of Niemann-Pick disease Type C ("NPC"). CytRx has an agreement with Orphazyme that can yield potential milestone payments and future royalties paid on sales of arimoclomol.

  • CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol
    Business Wire

    CytRx Highlights Orphazyme’s Acceleration of Pre-Launch Activities for Arimoclomol

    CytRx Corporation (OTCQB: CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted that Orphazyme A/S (ORPHA.CO) (NASDAQ:ORPH) ("Orphazyme") has announced new plans to accelerate commercial and other pre-launch activities during the fourth quarter of 2020 in preparation for potential approval of arimoclomol in Niemann-Pick disease Type C ("NPC"), which is currently under Priority Review by the U.S. Food and Drug Administration ("FDA") with a target action date of March 17, 2021. CytRx has an agreement with Orphazyme that can yield potential milestone payments and future royalties paid on sales of arimoclomol.